![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Woodward Pharma Services LLC, has acquired Lovaza (LO-VEY-ZA) soft gelatin capsules indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia from GlaxoSmithKline LLC (GSK).
Lead Product(s): Omega-3-Acid Ethyl Esters 90
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lovaza
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Woodward Pharma Services
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 18, 2021